| Literature DB >> 34561269 |
Stephen J Bagley1, Shawn Kothari1, Rifaquat Rahman2, Eudocia Q Lee3, Gavin P Dunn4, Evanthia Galanis5, Susan M Chang6, Louis Burt Nabors7, Manmeet S Ahluwalia8, Roger Stupp9, Minesh P Mehta10, David A Reardon3, Stuart A Grossman11, Erik P Sulman12, John H Sampson13, Simon Khagi14, Michael Weller15, Timothy F Cloughesy16, Patrick Y Wen3, Mustafa Khasraw13.
Abstract
Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as "recruiting" or "not yet recruiting" as of February 2021. ©2021 American Association for Cancer Research.Entities:
Mesh：
Year: 2022 PMID： 34561269 PMCID： PMC9044253 DOI： 10.1158/1078-0432.CCR-21-2750
Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 13.801